BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2025.
World J Gastrointest Surg. Oct 27, 2025; 17(10): 106685
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.106685
Table 2 Clinical characteristics of the modeling and validation sets, n (%)
Index
Modeling group (n = 253)
Validation group (n = 50)
P value
Gender0.416
Male167 (66.0)30 (60.0)
Female86 (34.0)20 (40.0)
Age (years)61 ± 962 ± 70.686
BMI (kg/m2)23.1 ± 2.722.4 ± 3.30.312
Alcohol consumption0.246
Yes48 (19.0)13 (26.0)
No205 (81.0)37 (74.0)
Smoking0.846
Yes110 (43.5)21 (42.0)
No143 (56.5)29 (58.0)
Diabetes0.983
Yes56 (22.1)11 (22.0)
No197 (77.9)39 (78.0)
Main pancreatic duct diameter (mm)3.8 ± 2.13.7 ± 2.20.606
Cutting edge pancreatic thickness (mm)15.3 ± 3.514.7 ± 3.10.220
Main pancreatic duct index0.3 ± 0.20.3 ± 0.20.885
Portal vein invasion0.901
Yes16 (6.3)4 (8.0)
No237 (93.7)46 (92.0)
Intra-abdominal fat thickness (mm)71.1 ± 27.268.3 ± 25.30.389
Pancreatic CT value (HU)38.6 ± 8.338.1 ± 8.80.693
Preoperative biliary drainage0.707
Yes30 (11.9)5 (10.0)
No223 (88.1)45 (90.0)
Preoperative laboratory examination
White blood cells6.1 ± 1.75.9 ± 1.60.397
Platelets232.5 ± 68.5240.3 ± 62.80.316
Albumin (g/L)39.3 ± 4.138.7 ± 3.80.662
Total bilirubin (μmol/L)121.3 (34.1-231.4)130.5 (39.2-190.0)0.747
Serum amylase (IU/L)25.0 (16.0-42.0)26.0 (19.5-39.3)0.737
CA19-9 (U/mL)81.9 (34.2-273.1)94.0 (28.5-357.5)0.626
Pancreatic intestinal anastomosis method0.814
Pancreatic duct jejunal mucosa vs mucosa47 (18.6)10 (20.0)
Pancreatic intestinal end to side insertion206 (81.4)40 (80.0)
Pancreatic cancer0.684
Yes59 (23.3)13 (26.0)
No194 (76.7)37 (74.0)
Postoperative pancreatic dysfunction
ISGPF0.517
Yes124 (49.0)22 (44.0)
No129 (51.0)28 (56.0)
ISGPS0.987
Yes61 (24.1)12 (24.0)
No192 (75.9)38 (76.0)
Surgical related deaths0.658
Yes8 (3.2)1 (2.0)
No245 (96.8)49 (98.0)


Write to the Help Desk